A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study

NCT02875548 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma (DLBCL)
Follicular Lymphoma (FL)
Synovial Sarcoma
Epitheliod Sarcoma (ES)
Mesothelioma
Advanced Solid Tumors
Renal Medullary Carcinoma
Non-Hodgkin Lymphoma (NHL)

Interventions

DRUG: Tazemetostat

Sponsor

Epizyme, Inc.